What to buy as Sensex dives below 59,500? Dilip Bhat answers
"Pharma is certainly one of the spaces that one should look at because that is one of the space which has not done anything at all. They have only gone down. I think one should definitely look into some of the frontline pharma stocks like Sun Pharma, Lupin, Cipla. I will also be a little more comfortable with something like Larsen & Toubro or Siemens or ABB."
Given severe under-performance, Indian market more likely to move up after Budget: Sandip Sabharwal
“The critical point for Tata Motors always was that the operating leverage is so huge that once the turnaround happens and if it sustains, then the profits which come will be so large that the stock becomes suddenly very cheap. Most analysts have projections of Rs 30 to 50 EPS for next year and the stock is cheap. We have bought into Tata Motors after a long time. There could be significant upsides over the next two years.”
Hot Stocks: Brokerages on Bajaj Auto, Dr Reddy’s Laboratories, Tata Motors and Cipla post Q3 results
EBITDA margin improved by 176 bps YoY to 24.2% despite soft Revlimid sales, mainly driven by an improvement in the mix. The net profit grew by 9.9% YoY to Rs8bn mainly on the back of a strong operational performance, which was partially offset by a higher tax rate on account of DTA reversal.
Q3 earnings, F&O expiry among 8 factors that will steer market this week
With earnings of index heavyweight Reliance out of the way, some major companies, including Axis Bank, Maruti Suzuki, Tata Motors, Bajaj Auto, Cipla, Bajaj Finance, Vedanta, and NTPC, among others, are slated to announce their third-quarter results this week. The markets on Monday will also react to RIL's earnings, which disappointed the Street, as well as other index majors ICICI Bank and Kotak Bank.
FY24 should see improvement in margins for pharma sector: Aditya Khemka
However, in FY24 what we believe is that the government will again allow pharma companies to take price increases anywhere in the range of 12% to 13% on the NLEM drugs and the non-NLEM drugs again about up to 10% which will help the price realisation in terms of growth.
Nithya Balasubramanian on 2 pharma names to bet on besides Sun & Cipla
“Coming to the complex generics opportunity, Cipla and Lupin are most exposed. We like Cipla more than Lupin because at least in the near term, there are multiple assets waiting to play out. For Cipla this year, we are hoping to see generic Advair, generic Abraxane which is most likely in the price but beyond that, there will be a generic Qvar, there will be a generic Teriparatide and potentially a generic Flovent as well.”
Cipla's higher automation spends to continue for 3 more years: CTO Geena Malhotra
The city-headquartered company started its investment journey on the automation front two years ago and has already been recognised for its work by multiple bodies, Geena Malhotra, the chief technology officer for the company, told PTI recently.